Results 51 to 60 of about 462,704 (302)

Assessing the accuracy of the updated Fujifilm SILVAMP TB LAM II assay between lot numbers

open access: yesIJTLD Open
BACKGROUND: The Fujifilm SILVAMP TB LAM (FujiLAM) assay, a point-of-care test detecting urine-based lipoarabinomannans, has demonstrated notable diagnostic accuracy for TB. However, FujiLAM exhibits lot-to-lot variability, limiting its clinical use.
K. Chikamatsu   +3 more
doaj   +1 more source

Accurate Detection of Rifampicin-Resistant Mycobacterium Tuberculosis Strains

open access: yesSensors, 2016
In 2013 alone, the death rate among the 9.0 million people infected with Mycobacterium tuberculosis (TB) worldwide was around 14%, which is unacceptably high. An empiric treatment of patients infected with TB or drug-resistant Mycobacterium tuberculosis (
Keum-Soo Song   +4 more
doaj   +1 more source

PolyTB: a genomic variation map for Mycobacterium tuberculosis [PDF]

open access: yes, 2014
Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) is the second major cause of death from an infectious disease worldwide. Recent advances in DNA sequencing are leading to the ability to generate whole genome information in clinical isolates ...
Gagneux, S.   +32 more
core   +1 more source

The First Case of Concomitant Mycobacterium genavense lymphadenitis and EBV-positive lymphoproliferative disorder

open access: yesMediterranean Journal of Hematology and Infectious Diseases, 2020
This is the first case of concurrent Mycobacterium genavense lymphadenitis and Epstein-Barr virus (EBV)-positive lymphoproliferative disorder (LPD) in the same lymph node with no immunocompromised history. M.
Yusuke Ito   +9 more
doaj   +1 more source

Aktivitas Anti Mycobacterium tuberculosis Strain H37Rv dan MDR (Multi Drug Resistant) dari Ekstrak Rimpang Curcuma mangga Val.

open access: yesJurnal Farmasi Galenika (Galenika Journal of Pharmacy), 2020
TB is an infectious disease caused by the bacterium Mycobacterium tuberculosis. Empirically the plants that have long been used in medicine are Curcuma mangga  rhizome, which shows pharmacological activity as an anti Mycobacterium tuberculosis drug.
Ritha Pratiwi   +3 more
doaj   +1 more source

Microevolution ofMycobacterium tuberculosisin a Tuberculosis Patient [PDF]

open access: yesJournal of Clinical Microbiology, 2010
ABSTRACTFiveMycobacterium tuberculosisisolates were obtained from three body sites from a Dutch patient. The isolates displayed a single genotype by 24-locus MIRU-VNTR typing (except for a single locus not amplified from one isolate) but were differentiated by small variations in IS6110fingerprints, spoligotypes, 6 hypervariable MIRU-VNTR loci, and/or ...
Al-Hajoj, SAM   +8 more
openaire   +5 more sources

Structures of mycobacterial 3‐methylcrotonyl‐CoA carboxylase reveal carrier‐domain translocation between catalytic sites

open access: yesFEBS Letters, EarlyView.
Mycobacterial 3‐methylcrotonyl‐CoA carboxylase uses a mobile biotin‐carrying domain to shuttle a carboxyl group between two catalytic sites, enabling carboxylation of 3‐methylcrotonyl‐CoA during leucine breakdown. Cryo‐electron microscopy captures the carrier at both sites and reveals an inward loop movement that may prevent futile rebinding to the ...
Ajit Yadav   +2 more
wiley   +1 more source

Mycobacterium tuberculosis is less likely to acquire pathogenic mutations during latent infection than during active disease

open access: yesMicrobiology Spectrum
Most people infected with Mycobacterium tuberculosis (Mtb) are believed to be in a state of latent tuberculosis (TB) infection (LTBI). Although LTBI is asymptomatic and not infectious, there is a risk of developing active disease even decades after ...
Asami Osugi   +5 more
doaj   +1 more source

Interference of Mycobacterium tuberculosis with macrophage responses [PDF]

open access: yes, 2009
Tuberculosis, caused by Mycobacterium tuberculosis, has become an important health and economic burden, with more than four thousand people succumbing to the disease every day.
Pieters, J.   +3 more
core  

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

open access: yesMolecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy